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 Context.—High-throughput automated immunoanalyz-
ers for hepatitis B virus serologic markers have been
introduced but have not been compared to existing
systems.
Objective.—To compare hepatitis B surface antigen,
hepatitis B surface antibody, and total hepatitis B core
antibody analyses between our Architect i2000 platform
and newer high-throughput fully automated immunoana-
lyzers.
Design.—From May to June 2018, a total of 932, 914,
and 1055 samples tested for hepatitis B surface antigen,
hepatitis B surface antibody, and total hepatitis B core
antibody, respectively, with the Architect i2000 system for
routine testing in our center were tested again with Alinity
i, Atellica IM, and Cobas e801 systems.
Results.—Total concordance rates among the systems
were 98.0%, 89.5%, and 93.0% for hepatitis B surface
antigen, hepatitis B surface antibody, and total hepatitis B
core antibody, respectively. Cohen’s j values exceeded
0.8. The correlations between serum hepatitis B surface
antibody levels quantified by all 4 systems were high (r .
0.85). The hepatitis B surface antibody averages were
greater for the Alinity i, Atellica IM, and Cobas e801 than
for the Architect i2000 (P , .001).
Conclusions.—Alinity i, Atellica IM, and Cobas e801
automated immunoanalyzers performed well when com-
pared with the existing Architect i2000 system with regard
to detection of hepatitis B viral infection. However, the
new systems have higher titer and positivity rates for
hepatitis B surface antibody and are more sensitive.
Notably, the Atellica IM has a lower positive rate for total
hepatitis B core antibody than does the Architect i2000.
(Arch Pathol Lab Med. 2020;144:612–619; doi: 10.5858/
arpa.2019-0096-OA)
Hepatitis B virus (HBV) infection, the major cause ofchronic hepatitis, cirrhosis, and hepatocellular carci-
noma worldwide, is an important global health problem
affecting human morbidity and mortality. Globally, more
than 2 billion people have been or are currently infected
with HBV, and more than 248 million people are currently
positive for hepatitis B surface antigen (HBsAg).1,2 South
Korea is an intermediate endemic area for HBV, with a
prevalence between 2% and 7%.3
Serologic analysis, in combination with viral markers,
plays an important role in HBV infection screening in HBV-
endemic areas, disease progression monitoring in HBV
carriers, treatment selection, and confirming response to
therapy.4–10 Serologic methods include enzyme immunoas-
say, microparticle enzyme immunoassay, radioimmunoas-
say, and reverse passive hemagglutination, all of which are
used to test for markers of HBV infection.11–14 However,
since the introduction of the chemiluminescent immunoas-
say, analyses based on this principle have been used in
many hospitals, with the Abbott Architect i2000 (Abbott
Diagnostics, Abbott Park, Illinois) being the representative
platform.15 In our facility, we plan to replace this system
with a recently adopted high-throughput fully automated
immunoanalyzer, as we intend to introduce total laboratory
automation.
In this study, we therefore compared the results for
HBsAg, anti–hepatitis B surface antibody (anti-HBs), and
total anti–hepatitis B core antibody (anti-HBc), which are
the major serologic markers for HBV infection, using our
existing equipment, the Architect i2000, and recently
adopted high-throughput fully automated immunoanalyz-
ers: the Abbott Alinity i (Abbott Diagnostics), Siemens
Atellica IM (Siemens Healthineers, Tarrytown, New York),
and Roche Cobas e801 (Roche Diagnostics GmbH, Mann-
heim, Germany). A comparison of HBV serologic marker




Three serologic markers were selected for comparison: HBsAg,
anti-HBs, and anti-HBc. These markers were selected because they
are more often requested for evaluation than serologic markers for
human immunodeficiency virus infection or hepatitis C virus
infection. In total, 932, 914, and 1055 serum samples tested with
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the existing Architect i2000 system at Severance Hospital from May
to June 2018 were submitted for HBsAg, anti-HBs, and anti-HBc
analysis, respectively. These samples were residual specimens for
which HBV clinical testing was requested. The specimens were
stored at 48C, and testing with the other devices was completed
within a few days. Specimens were tested with Alinity i, Atellica
IM, and Cobas e801 systems. At that time, the anti-HBc test with
Cobas e801 was not approved and was thus excluded. The Alinity i
is the next version of the Architect i2000 made by Abbott and
measures serologic markers, using the same principle and kit as its
predecessor. This study was approved by the Institutional Review
Board of Yonsei University of Medicine (Seoul, Republic of Korea).
Assays and Methods
HBsAg, anti-HBs, and anti-HBc were qualified by using the
Architect i2000, Alinity i, Atellica IM, and Cobas e801. Reagents for
the Architect i2000 and Alinity i included the HBsAg Qualitative II
Reagent Kit, Anti-HBs Reagent Kit, and Anti-HBc II (all from
Abbott Diagnostics). Reagents for the Atellica IM included the
Hepatitis B surface Antigen II, Anti-Hepatitis B surface Antigen 2,
and Anti-Hepatitis B core Total (all from Siemens Healthineers).
Reagents for the Cobas e801 included the Elecsys HBsAg II, Elecsys
Anti-HBs II, and Elecsys Anti-HBc II (all from Roche Diagnostics
GmbH). The characteristics of each system are presented in Table
1. All 4 systems make use of chemiluminescence assays. However,
in the Cobas e801, anti-HBc is assessed by using a competitive
assay, while the other platforms use sandwich immunoassays.
Furthermore, the Cobas e801 uses ruthenium as its chemilumi-
nescent material, while the other systems use acridinium. The
minimum sample volume is the smallest in the Cobas e801.
Interpretation of anti-HBs results is done in the same way for all 4
machines but varies slightly for HBsAg and anti-HBc results. The
number of testable samples per hour is the highest in the Atellica
IM. Time to first result is 29 minutes for the Architect i2000 and
Alinity i, 14 to 46 minutes for the Atellica IM, and 18 to 27 minutes
for the Cobas e801. Reagent stability and specimen storage vary
from system to system.
The Architect i2000 and Alinity i systems both use 2-step
sandwich chemiluminescent microparticle immunoassay technol-
ogy. Sample and acridinium-labeled conjugate are mixed with
HBsAg, HBcAg, or anti-HBs coated with paramagnetic micropar-
ticles. The resulting chemiluminescent reaction is measured as
relative light units (RLUs). There is a direct relationship between
the amount of analytes in the sample and the RLUs detected by the
system optics. HBsAg and anti-HBc are determined qualitatively,
while anti-HBs is determined quantitatively. In the former case, the
systems calculate results by using the ratio of the sample RLU to
the cutoff RLU (S/CO) for each specimen and control. Samples
with a value of 1.0 or greater are considered reactive for HBsAg or
anti-HBc. For anti-HBs, however, these systems use a 4-parameter
logistic curve fit data reduction method for calibration and to
generate results. Anti-HBs concentrations of 10 IU/L or greater are
considered to be protective against HBV infection. The measuring
interval for anti-HBs is 2.00 to 1000.00 IU/L. If initial results
indicate reactivity for HBsAg and anti-HBc, a retest in duplicate is
needed. For HBsAg, repeatedly reactive specimens must be
confirmed by using a neutralizing assay before disclosing the
HBsAg status to the patient.
The Atellica IM system uses sandwich chemiluminometric
immunoassay technology. Sample and streptavidin-coated para-
magnetic microparticles are combined with biotinylated HBsAg
and acridinium ester–labeled HBsAg, biotinylated HBcAg and
acridinium ester–labeled HBcAg, or biotinylated anti-HBs and
acridinium ester–labeled anti-HBs. A direct relationship exists
between the amount of analytes present in the patient sample and
the amount of RLUs detected by the system, and the result is
determined according to the index value established with the
calibrators. For HBsAg and anti-HBc samples with values of 1.0 and
greater and values of 0.50 and greater, respectively, the indexes are
considered reactive. Anti-HBs with concentration values of 10 IU/L
or greater are considered to be reactive. The measuring interval for
anti-HBs is 3.1 to 1000.0 IU/L. Samples with an index value of at
least 1.0 but lower than 50.0 are considered reactive for HbsAg, but
the test must be repeated in duplicate. Samples with an initial value
of at least 8.0 IU/L but lower than 12.0 IU/L should be retested in
duplicate for anti-HBs.
The Cobas e801 system uses electrochemiluminescence immu-
noassay technology. In this system, HBsAg and anti-HBs, and anti-
HBc, are analyzed by using sandwich and competition immuno-
assays, respectively. The system uses the interaction of biotin and
streptavidin with the ruthenium complex as chemiluminescent
material. Application of a voltage to the instrument’s electrode
induces a chemiluminescent emission, which is measured by a
photomultiplier. The analysis results are determined automatically
by the instrument software, which compares the electrochemilu-
minescence signal obtained from the product of sample reaction
with the signal of the cutoff value obtained during calibration. For
HBsAg, a cutoff index (COI) of 1.0 or greater is considered reactive,
while values in the range of 0.9 to less than 1.0 are considered
borderline. For anti-HBc, a COI value of 1.0 or less is considered
reactive. For anti-HBs, results of 10 IU/L or greater are considered
positive. The measuring interval for anti-HBs is 2.0 to 1000.0 IU/L.
Retesting of samples with an initial COI of 0.90 or greater can be
automatically performed for HBsAg. For anti-HBc, retesting of
samples with an initial COI of 1.0 or less can be automatically
performed.
Statistical Analysis
All statistical analyses were performed with Analyse-it Method
Validation Edition, version 3.5 (Analyse-it Software, Leeds,
England). We used concordance rates to establish the validity of
recently adopted high-throughput fully automated immunoana-
lyzers for detecting HBV infection. The serologic tests for HBV
infection are essentially qualitative. To test the reliability of
concordance between the systems, the Cohen’s j value was used.
Anti-HBs titers between systems were compared by using the
Pearson correlation coefficient, Passing-Bablok regression, and
paired t tests. A P value of ,.05 was considered statistically
significant.
RESULTS
The positivity rates of HBsAg, anti-HBs, and anti-HBc for
specimen analyses using the Architect i2000 were 21.0%
(196 of 932), 55.7% (509 of 914), and 53.6% (565 of 1055),
respectively. The total concordance rates among the 4
systems were 98.1% (914 of 932), 89.4% (817 of 914), and
93.0% (981 of 1055) for HBsAg, anti-HBs, and anti-HBc,
respectively (Table 2). The 18 specimens with inconsistent
HBsAg results were all negative in testing with Alinity i
(Table 3). According to HBV DNA levels, aspartate
aminotransferase/alanine aminotransferase levels, or fol-
low-up HBsAg results after several months, all of these
HBsAg results appeared to be negative. In addition, the
patients had not recently been vaccinated and had a low
HBsAg value of 0 to 10 units. Most false-positive results
were observed with Atellica IM and Cobas e801. Most of the
positive values of the samples showing discrepant results for
anti-HBs were lower than 30 IU/L. Discrepancies in anti-
HBc results were predominantly observed in specimens that
were reactive in the Architect i2000 but negative in the
Atellica IM (61 of 74, 82.4%). The median values of
discrepant serologic markers related to HBV infection
ranged from 0.19 to 1.10 for HBsAg, 5.84 to 13.90 for anti-
HBs, and 0.27 to 1.66 for anti-HBc. The concordance rates
between the respective systems all exceeded 90%, and
Cohen’s j values were also greater than 0.8 (Table 4). Of the
3 markers, HBsAg had the highest concordance rates,
exceeding 98%. The correlations between the serum anti-
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HBs levels measured quantitatively by the 4 systems were all
high (r . 0.85) (Figure).
DISCUSSION
Despite advances in molecular genetic methods, serum
HBV markers have retained their importance in the clinical
screening and diagnosis of HBV infection in countries that
do not have molecular genetic facilities. Currently, the
chemiluminescent immunoassay method is the most widely
used for serum HBV markers. Recently, high-throughput
fully automated immunoanalyzers have been introduced for
total laboratory automation. These are based on the










Principle CMIA CMIA CLIA ECLIA
HBsAg Sandwich Sandwich Sandwich Sandwich
Anti-HBs Sandwich Sandwich Sandwich Sandwich
Anti-HBc Sandwich Sandwich Sandwich Competition
Chemiluminescent
material
Acridinium Acridinium Acridinium Ruthenium
Sample volume
HBsAg 75 lL 56 lL 100 lL 30 lL
Anti-HBs 75 lL 75 lL 100 lL 24 lL











COI ¼ Signal sample/cutoff
,0.9 Nonreactive



























COI ¼ Signal sample/cutoff
.1.0 Nonreactive
1.0 Reactive
No. of testable samples
per hour
200 200 400 300
Time to first result
HBsAg 29 min 29 min 26 min 18 min
Anti-HBs 29 min 29 min 14 min 18 min
Anti-HBc 29 min 29 min 46 min 27 min










HBsAg: on board, system
temperature, 60 d
Anti-HBs: on board, system
temperature, 90 d
Anti-HBc: on board,








28C–88C, up to 6 days
Room temperature
(208C–258C), 24 h
28C–88C, up to 6 d
28C–88C, up to 7 d Room temperature
(208C–258C), up to 6 d
28C–88C, up to 14 d
Anti-HBs Room temperature
(208C–258C), 24 h
28C–88C, up to 14 days
Room temperature
(208C–258C), 24 h
28C–88C, up to 14 d
28C–88C, up to 7 d Room temperature
(208C–258C), up to 3 d
28C–88C, up to 6 d
Anti-HBc Room temperature
(208C–258C), up to 3 d
28C–88C, up to 14 d
Room temperature
(208C–258C), up to 3 d
28C–88C, up to 7 d
28C–88C, up to 7 d Room temperature
(208C–258C), up to 7 d
28C–88C, up to 14 d
Interference Biotin, bilirubin, triglycerides, protein, hemoglobin
Abbreviations: Anti-HBc, hepatitis B core antibody; Anti-HBs, hepatitis B surface antibody; CLIA, chemiluminometric immunoassay; CMIA,
chemiluminescent microparticle immunoassay; COI, cutoff index; ECLIA, electrochemiluminescence immunoassay; HBsAg, hepatitis B surface
antigen; S/CO, sample relative light unit/cutoff relative light unit.
a Abbott Park, Illinois.
b Tarrytown, New York.
c Mannheim, Germany.
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chemiluminescent immunoassay method but are more
efficient than standard tests. In this study, we compared
the results of HBsAg, anti-HBs, and anti-HBc analyses
among 3 recently adopted high-throughput fully automated
immunoanalyzers (Alinity i, Atellica IM, and Cobas e801)
and our existing equipment (Architect i2000). A comparison
of these new systems and the Architect i2000 has not been
reported previously.
Reactive HBsAg results indicate HBV infection, which can
be either acute or chronic. HBsAg is related to HBV DNA,
and also to increased risk of liver cancer.16–18 Furthermore, it
may be a predictor of treatment outcome.19 In HBsAg, high
concordance rates of greater than 98% were observed when
all 4 systems were compared, simultaneously or in pairs, and
were significantly higher than the rates of other markers
(anti-HBs, anti-HBc). The antigen test appears to return
more constant values, regardless of the system, than are
seen with the antibody test.
Reactive anti-HBs results indicate that the testee has
successfully responded to the hepatitis B vaccine, or has
recovered from acute hepatitis B. This means that the
patient will be immune to hepatitis B in the future. Anti-HBs
with concentration values of 10 IU/L or greater are
considered to be reactive and immune to hepatitis B.20 This
test is necessary to check the effect of the vaccine, or to find
subjects requiring booster injections because of decreases in
anti-HBs levels over time.21 Anti-HBs is the only quantita-
tive measure. Concordance rates between the systems were
greater than 90%, and the Cohen’s j values between
systems were greater than 0.8 (Table 4). The results of the
anti-HBs analyses were in very good agreement. In addition,
the correlation coefficients of anti-HBs titers between the
systems exceeded 0.85, indicating good correlations be-
tween the analyses. In the Architect i2000 system, however,
negative anti-HBs results tended to be reactive in the new
equipment (92 of 97, 94.8%), and the anti-HBs mean was







Architect i2000a Alinity ia Atellica IMb Cobas e801c



















Not tested Negative Normal range 0.19 N 0.59 N 1.21 R 1.06 R
P5 Herniated
cervical disc
Not tested Negative Normal range 0.15 N 0.28 N 4.43 R 0.41 N
P6 Endometrial
polyp




Not tested Negative Normal range 0.18 N 0.36 N 15.60 R 0.43 N
P8 Acute rhinitis Not tested Negative Normal range 0.17 N 0.28 N 3.09 R 0.46 N
P9 Physical
examination




Not tested Negative Normal range 0.17 N 0.29 N 1.33 R 0.34 N
P11 S/P kidney
transplant





Negative Normal range 0.21 N 0.29 N 0.08 N 1.43 R
P13 Proteinuria Not tested Negative Normal range 0.34 N 0.44 N 0.06 N 1.13 R
P14 Rectal cancer Not tested Negative Normal range 0.19 N 0.37 N 0.13 N 9.00 R
P15 Endometrial
polyp




Not tested Negative Normal range 0.21 N 0.32 N 0.12 N 1.13 R
P17 S/P kidney
transplant
Not tested Negative Normal range 0.15 N 0.28 N 0.29 N 1.67 R
P18 S/P kidney
transplant
Not tested Negative Normal range 0.19 N 0.23 N 0.01 N 1.07 R
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; COI; cutoff index; HBsAg, hepatitis B surface antigen; N, negative; R,
reactive; PCR, polymerase chain reaction; S/CO, sample relative light unit/cutoff relative light unit; S/P, status post.
a Abbott Diagnostics, Abbott Park, Illinois.
b Siemens Healthineers, Tarrytown, New York.
c Roche Diagnostics GmbH, Mannheim, Germany.
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Comparison of hepatitis B surface antibody titers (IU/L) excluding the results above 1000 IU/L. A, Architect i2000 and Alinity i. B, Architect i2000
and Atellica IM. C, Architect i2000 and Cobas e801. D, Alinity i and Atellica IM. E, Alinity i and Cobas e801. F, Atellica IM and Cobas e801.
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greater in the Alinity i, Atellica IM, and Cobas e801 than in
the Architect i2000 (P , .001). As shown in the Figure, the
order of magnitude of the slopes of regression line was
Cobas e801, Atellica IM, Alinity i, and Architect i2000, which
should be considered when setting the desired concentra-
tion in each hospital. The new systems appear to be more
sensitive toward anti-HBs than the existing equipment,
which may be attributed to differences in the subtypes of
HBV antigen in the reagents or in the method of antigen
preparation. Considering the frequent migration of patients
or clinicians between medical institutions, the comparison
of these test methods may facilitate accurate determination
and interpretation of the test results by analyzing qualitative
agreement rates and discrepancies. Total anti-HBc appears
at the onset of symptoms in acute HBV infection and
persists for life. The presence of anti-HBc indicates previous
or ongoing HBV infection in an undefined time frame. This
marker can be used to determine whether positive anti-HBs
reaction in a patient is due to vaccination or past infection.
Indeed, occult HBV infection is known to be associated with
‘‘anti-HBc alone’’ subjects who are identified as positive for
total anti-HBc, but negative for both HbsAg and anti-HBs.22
The anti-HBc results in the Atellica IM (512 of 1055; 48.5%)
were less positive than those in the Architect i2000 (565 of
1055; 53.6%) and Alinity i (569 of 1055; 53.9%), and tended
to be in lesser agreement with results of the other systems.
All 60 patients who were only anti-HBc negative according
to Atellica IM were negative for HBsAg and had no history
or remarkable clinical symptoms; therefore, these results
were likely false positives, but this remains unknown
because we have not evaluated any other tests.
The median discordant HBsAg values were 0.19 (0.14–
4.76), 0.31 (0.21–0.97), 0.41 (0.01–10.03), and 1.10 (0.33–
9.00), while the median discordant anti-HBs values were
5.84 (0.25–20.89), 7.53 (0.18–26.83), 10.51 (1.36–61.87), and
13.9 (2.00–107.00) for the Architect i2000, Alinity i, Atellica
IM, and Cobas e801 platforms, respectively. Furthermore,
the median discordant anti-HBc values were 1.66 (0.08–
8.04), 1.81 (0.02–2.22), and 0.27 (0.13–9.05) for Architect
i2000, Alinity i, and Atellica IM, respectively. The cutoff
value for HBsAg in all 4 systems, and of anti-HBc in
Architect i2000 and Alinity I, was 1.0; the cutoff value of
anti-HBc in Atellica IM was 0.5; and the cutoff value for
anti-HBs in all 4 systems was 10 IU/L. Therefore, the
discordant values of serologic markers related to HBV
infection were near the cutoff. Serologic results of HBV
infection near the cutoff should be judged by re-examina-
tion and consideration of clinical signs or other markers.
The main limitation of this study was that the remainders
of specimens used for other clinical tests were evaluated.
Thus, the amount of the specimen was insufficient for
retesting of specimens that showed inconsistent results.
In conclusion, the fully automated immunoanalyzers
(Alinity i, Atellica IM, and Cobas e801) used to detect
HBV infection performed well when compared with our
existing Architect i2000 system. Because of the different
sample volumes and throughput of each system, the choice
of which to use depends on the hospital conditions;
however, it should be noted that the new systems show
higher titers and positivity rates for anti-HBs than the
Architect i2000, and are also more sensitive. It should also
be noted that the Atellica IM has a lower positive rate than
does the Architect i2000. Because the results presented were
from a single center, they should be confirmed by future
studies using results from multiple centers.
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